NCT00923663
Unknown
2 期
Phase II Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
概览
- 阶段
- 2 期
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Rate of objective responses induced by Lenalidomide
概览
简要总结
The activity of monotherapy with Lenalidomide will be evaluated in patients with lymphoma of the mucosa associated lymphoid tissue (MALT).
详细描述
The primary objective of the study is to evaluate the clinical potential of Lenalidomide to induce objective/histologic responses in patients with MALT lymphoma.
The secondary objectives are to evaluate the safety of Lenalidomide in this patient population and to evaluate the impact of Lenalidomide on progression free survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histologically confirmed MALT lymphoma with measurable disease (stage I - IV)
- •With first or greater relapse after HP-eradication, radiation or chemotherapy in case of gastric lymphoma
- •Age \> 18 years
- •Must be able to tolerate therapy, and have adequate cardiac, renal, and hepatic function, ECOG status of 0 - 2
- •Must be capable of understanding the purpose of the study and have given written informed consent
排除标准
- •Lymphoma histology other than MALT lymphoma or MALT lymphoma with a diffuse large cell lymphoma ("high grade lymphoma") - component
- •Use of any investigational agent within 28 days prior to initiation of treatment with lenalidomide
- •History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 5 years
- •Major surgery, other than diagnostic surgery, within the last 4 weeks
- •Evidence of CNS involvement
- •A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs
- •Severe peripheral polyneuropathy
- •Clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 6 months
- •Inadequate hematological status at baseline prior to study entry: Dependency on red blood cell and/or platelet transfusions, ANC (absolute neutrophil count (segmented + bands)) \< 1.0 x 109/L
- •Patients with active opportunistic infections
研究组 & 干预措施
Lenalidomide
Experimental
Lenalidomide administered orally at a dose of 25 mg daily
干预措施: Lenalidomide (Drug)
结局指标
主要结局
Rate of objective responses induced by Lenalidomide
时间窗: 24 months
次要结局
- Time to progression(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaStage IV Chronic Lymphocytic LeukemiaNCT01271283National Cancer Institute (NCI)
已完成
2 期
Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's LymphomaHodgkin DiseaseNCT00478959University Health Network, Toronto30
已完成
2 期
Lenalidomide as Second-line Treatment for Advanced Hepatocellular CarcinomaLiver CancerNCT01545804National Taiwan University Hospital55
已完成
2 期
Lenalidomide Plus Rituxan for Untreated Mantle Cell LymphomaMantle Cell LymphomaNCT01472562Weill Medical College of Cornell University38
已完成
2 期
A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell LymphomaRelapsed/Refractory Mantle Cell LymphomaNCT02460276Lund University Hospital50